Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.58 |
| ▸ | BTK | Q06187 | 5/20 | 0.50 |
| ▸ | KIF11 | P52732 | 3/20 | 0.42 |
| ▸ | ALDH2 | P05091 | 3/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15394541 | 0.82 | NOTUM (0.59) | NOTUMBTKKIF11ALDH2HDAC6 | |
| SCHEMBL133043 | 0.81 | NOTUM (0.58) | NOTUMKIF11ALDH2DHODHMAP4K4 | |
| SCHEMBL6042142 | 0.79 | NOTUM (0.77) | NOTUMALDH2MAP4K4HDAC6L3MBTL1 | |
| SCHEMBL94548 | 0.79 | NOTUM (0.64) | NOTUMALDH2MAP4K4HDAC6PARP1 | |
| SCHEMBL2054595 | 0.78 | NOTUM (0.42) | NOTUMBTKKIF11HDAC6NPC1 | |
| SCHEMBL25065125 | 0.76 | NOTUM (0.47) | NOTUMBTKALDH2MAP4K4HDAC6 | |
| SCHEMBL22560194 | 0.76 | BTK (0.43) | NOTUMBTKMAP4K4HDAC6XDH | |
| SCHEMBL4231200 | 0.75 | NOTUM (0.64) | NOTUMBTKALDH2MAP4K4HDAC6 | |
| SCHEMBL3476831 | 0.75 | NOTUM (0.64) | NOTUMALDH2MAP4K4ALDH1A1 | |
| SCHEMBL3901501 | 0.75 | NOTUM (0.64) | NOTUMALDH2MAP4K4HDAC6CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709501-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709501-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709501-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2010-05-04 | — | — | US | disclosed |
| WO-2007076104-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070149513-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149513-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149513-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149513-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | NOTUM 4484/4885BTK 835/4885KIF11 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.